Tissue Nanotransfection Technology

Tissue nanotransfection (TNT) is a pioneering, non-invasive technology developed under the leadership of Director Chandan K. Sen, PhD. This approach uses a compact silicon nanochip device that delivers genetic material into living tissue with a mild electrical pulse, reprogramming cells directly at the injury site without viruses, stem cell harvesting, or laboratory processing.

The process converts existing skin cells into needed types, such as blood vessel or nerve cells, in less than a second. In preclinical models, TNT has restored blood flow in limbs with restricted circulation, accelerated healing of diabetic wounds, and supported nerve regeneration. Recent advancements include targeted gene editing to rescue perfusion in diabetic ischemic wounds, as highlighted in 2024 publications. The technology enables the body to serve as its own repair system, offering point-of-care application for conditions like burns, peripheral artery disease, and traumatic injuries.

Recognized for its innovation, TNT has been licensed for commercial development and holds promise for treating stroke, organ damage, and military injuries. Unlike traditional methods requiring invasive procedures, TNT minimizes risks and hospital stays, making it suitable for emergency and remote settings. Ongoing research refines delivery for various tissues and combines it with other therapies to enhance effectiveness.

By harnessing the body’s cells for regeneration, TNT represents a transformative step in regenerative medicine, aiming to improve outcomes for millions affected by chronic wounds and tissue loss through safe, efficient, and accessible treatments.